No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home COUNTRY BENELUX

dsm-firmenich to sell stake in Feed Enzymes Alliance to its partner Novonesis for €1.5 billion

Cisionby Cision
February 11, 2025
Reading Time: 5 mins read
in BENELUX, DACH, GREEN, PRIVATE EQUITY
Share on FacebookShare on Twitter

KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, Feb. 11, 2025 /PRNewswire/ — dsm-firmenich, innovators in nutrition, health, and beauty, today announces the sale of its stake in the Feed Enzymes Alliance to its equal partner Novonesis, a global leader in biosolutions, for €1.5 billion.

dsm-firmenich logo

The dsm-firmenich activities to be sold under this transaction to Novonesis represented in 2024 approximately €300 million in total annual net sales. Novonesis will continue a long-term commercial relationship with the Animal Nutrition & Health business, for the re-sale of its feed enzymes through the Animal Nutrition & Health world-class premix network.

dsm-firmenich expects to receive approximately €1.4 billion net in cash, after transaction costs and capital gains tax, and anticipates a book profit on the transaction to be recognized upon closing.

Through a unique alliance formed more than 25 years ago, dsm-firmenich and Novonesis have jointly developed the industry’s most competitive, comprehensive and innovative feed enzymes portfolio for the animal feed markets.

At dsm-firmenich, the feed enzymes business is currently part of the Animal Nutrition & Health business unit, which itself will be separated from the Group to operate under new ownership, as announced in February 2024. In the context of this separation, the partners evaluated the future of their Alliance and concluded that unwinding the Alliance would be strategically beneficial for both partners.

Dimitri de Vreeze, CEO of dsm-firmenich, commented: “The Alliance has been a great success for both companies, establishing a global leadership position in feed enzymes. I am confident that this business will continue to thrive under the leadership of Novonesis, and I am pleased that the long-term commercial relationship with our Animal Nutrition & Health business will continue. At the same time, we are on track with the finetuning of our portfolio and next week we will begin the process of seeking transaction options to exit the Animal Nutrition & Health business from the Group over the course of 2025.”

Ester Baiget, President and CEO of Novonesis, said: “We are thrilled to announce the strategic acquisition of dsm-firmenich’s portion of the Alliance. Growing global protein demand, coupled with increasing land and water scarcity, requires innovative solutions. Now with an expanded presence across the animal biosolutions value chain, we are better positioned to create more value for customers with sustainable value adding biosolutions.”

dsm-firmenich remains committed to separate the Animal Nutrition & Health business from the Group in the course of 2025. With the scope of the separation of the Animal Nutrition & Health business now defined, dsm-firmenich will begin next week the process of seeking transaction options to exit Animal Nutrition & Health. Further announcements will be made as and when appropriate.

This transaction is expected to be completed in the course of 2025, subject to customary conditions and regulatory approvals.

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com 

About Novonesis
Novonesis is a global company leading the era of biosolutions. By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology.

For more information

Media relations

Investor relations

Robin Roothans

Dave Huizing

tel. +41 (0)79 280 03 96

tel. +31 (0)88 425 7306

e-mail media@dsm-firmenich.com

e-mail investors@dsm-firmenich.com

Forward-looking statements
This press release may contain forward-looking statements with respect to dsm-firmenich’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.  The English language version of the press release is leading.

Logo – https://mma.prnewswire.com/media/2071772/5159952/dsm_firmenich_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/dsm-firmenich-to-sell-stake-in-feed-enzymes-alliance-to-its-partner-novonesis-for-1-5-billion-302373127.html

Read the orginal article: undefined

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

FRANCE

French quantum startup Quobly raises €21m for development of 100 qubit chip

May 25, 2025
GREEN

Northvolt to shut down operations by end of June

May 25, 2025
FRANCE

Amadeus signs cloud computing agreement with Google

May 24, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post
$97.4B offer from Elon Musk and co-investors for OpenAI. Founder Sam Altman sends it back to sender

$97.4B offer from Elon Musk and co-investors for OpenAI. Founder Sam Altman sends it back to sender

Italy’s angels & incubators and venture capital weekly roundup. News from Ydun, Limestone Capital, Genoa Instruments, Deep Blue Ventures, and more

Italy’s angels & incubators and venture capital weekly roundup. News from Ydun, Limestone Capital, Genoa Instruments, Deep Blue Ventures, and more

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart